UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     
Date of Report (Date of Earliest Event Reported):   June 20, 2012

ADVENTRX Pharmaceuticals, Inc.
__________________________________________
(Exact name of registrant as specified in its charter)

     
Delaware 001-32157 84-1318182
_____________________
(State or other jurisdiction 		_____________
(Commission 		______________
(I.R.S. Employer
of incorporation) File Number) Identification No.)
      
12390 El Camino Real, Suite 150, San Diego, California   92130
_________________________________
(Address of principal executive offices) 		  ___________
(Zip Code)
     
Registrant’s telephone number, including area code:   858-552-0866

Not Applicable
______________________________________________
Former name or former address, if changed since last report

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.07. Submission of Matters to a Vote of Security Holders.

On June 20, 2012, ADVENTRX Pharmaceuticals, Inc. (the “Company”) held its 2012 Annual Meeting of Stockholders (the “Annual Meeting”). The following is a brief description of each matter voted upon at the Annual Meeting and the number of votes cast for and against, as well as the number of abstentions and broker non-votes as to each such matter, as applicable.

1.   To elect four directors to hold office until the next annual meeting of stockholders and until their successors are elected and qualified or until their earlier resignation or removal:
                                 
                   Broker
    For   Against   Abstain   Non-Vote
Nominee                                
Brian M. Culley
    11,904,371       647,235       219,473       22,437,754  
Jack Lief
    11,534,421       1,009,830       226,828       22,437,754  
David A. Ramsay
    11,542,279       1,005,922       222,878       22,437,754  
Lewis J. Shuster
    11,538,031       1,006,180       226,868       22,437,754  

In accordance with the above results, each nominee was elected to serve as director.

2.   To ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2012:
                                 
      For   Against   Abstain   Broker
                            Non-Vote
                                  
  
    34,696,766       474,146       37,921       0  

In accordance with the above results, the appointment of PricewaterhouseCoopers LLP was ratified.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

         
    ADVENTRX Pharmaceuticals, Inc.
          
June 21, 2012   By:   /s/ Patrick L. Keran
       
        Name: Patrick L. Keran
        Title: President and Chief Operating Officer
Adventrx (AMEX:ANX)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Adventrx Charts.
Adventrx (AMEX:ANX)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Adventrx Charts.